doi: 10.1136/heartjnl-2021-319629.
Epub 2021 Nov 23.
Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Affiliations
- PMID: 34815331
- DOI: 10.1136/heartjnl-2021-319629
Item in Clipboard
Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Heart.
2022 Jan.
No abstract available
Conflict of interest statement
Competing interests: AFS has received Servier funding for unrelated work.
Similar articles
-
Do PCSK9 inhibitors reduce cardiovascular events?Can Fam Physician. 2018 Sep;64(9):669. Can Fam Physician. 2018. PMID: 30209099 Free PMC article. No abstract available.
-
Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.Heart. 2018 Jul;104(13):1053-1055. doi: 10.1136/heartjnl-2017-312858. Epub 2018 Feb 14. Heart. 2018. PMID: 29444808 No abstract available.
-
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.Endocrinol Diabetes Nutr. 2017 Aug-Sep;64(7):341-344. doi: 10.1016/j.endinu.2017.04.005. Epub 2017 Jun 3. Endocrinol Diabetes Nutr. 2017. PMID: 28745604 English, Spanish. No abstract available.
-
[Anti-PCSK9 antibodies in type 2 diabetes and secondary prevention of cardiovascular diseases].Clin Investig Arterioscler. 2016 May;28 Suppl 2:31-38. doi: 10.1016/S0214-9168(16)30168-1. Clin Investig Arterioscler. 2016. PMID: 27888904 Review. Spanish.
-
[Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].Ugeskr Laeger. 2015 Mar 9;177(11):V11140582. Ugeskr Laeger. 2015. PMID: 25786699 Review. Danish.
Cited by
-
Quantitative assessment of baseline imbalances in evolocumab and alirocumab trials: a meta-epidemiological study.BMC Med Res Methodol. 2024 Jun 22;24(1):137. doi: 10.1186/s12874-024-02260-z. BMC Med Res Methodol. 2024. PMID: 38909176 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
